hotspot -WSS

hotspot

author：comprehensive 2025-08-24 23:27:57 - browse：796

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Kaiser Permanente unions announce official strike date

WSS

How one patient went off dialysis — and others can too

Data show record exodus of life scientists from academia

Micronoma's microbiome cancer diagnostic approach under fire

Senator probes 340B programs at Cleveland Clinic, Bon Secours

What the US credit downgrade means for the economy, your finances

STAT Virtual Event: How to Increase Diversity in Clinical Trials

focus

hotspot

focus

Bright Health sells Medicare Advantage business to Molina

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

23andMe had bad news about my health. I wish a person had delivered it

Menendez indictment could see pharma lose a key ally

Sports medicine is finally prioritizing gender equality

Biogen shutters digital health group, ends Apple study, in cost cutting move

How one medical school became remarkably diverse

FDA seeks to regulate lab

Apple is now the first public company to be valued at $3 trillion

5 important ways Henrietta Lacks changed medical science

explore

Micronoma's microbiome cancer diagnostic approach under fire

After a drawn out lobbying fight, ARPA

EQRx, failed developer of low

Amazon expands telehealth clinic nationwide

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Did you have Obamacare on your GOP debate bingo card?

focus

knowledge

focus

leisure time